Status:
COMPLETED
Comparison of HFNC With NIV in Weaning COPD
Lead Sponsor:
Jie Li
Collaborating Sponsors:
Binzhou Medical University
Conditions:
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Eligibility:
All Genders
21-90 years
Phase:
NA
Brief Summary
High flow nasal cannula (HFNC) has been shown to improve oxygenation and facilitate weaning in hypoxemia patients. Some clinical studies show the benefits of using HFNC in COPD patients, including red...
Detailed Description
High flow nasal cannula (HFNC) provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation. In a recent meta-analysis of seven trials wit...
Eligibility Criteria
Inclusion
- Intubated patients with Chronic obstructive pulmonary disease exacerbation
- Meeting extubation criteria (Pulmonary infection control window)
- Age \> 21years and \< 90 years
Exclusion
- Tracheotomy
- Combined with severe dysfunction of other organs, including heart, brain, liver, and renal failure;
- Hemodynamic instability
- Contraindication to NIV: cannot use mask, such as facial injury, burns or deformities; cannot cooperate with NIV such as delirium; copious secretions with weak cough ability; gastric over distention, and vomiting;
- Contraindication to HFNC: rhinitis, nasal congestion, deformities or blockage.
- Weak cough ability with copious secretions
- Refuse to participate in the study
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2018
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03458364
Start Date
January 1 2017
End Date
July 30 2018
Last Update
August 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Binzhou Medical University Hospital
Yantai, Shandong, China, 264003